Tatiana Hurtado de Mendoza, PhD, is the first author of the study and assistant project scientist at UC San Diego and Moores Cancer Center.
Andrew Lowy, MD, is the co-corresponding author of the study, professor of surgery at UC San Diego School of Medicine and chief of the Division of Surgical Oncology at Moores Cancer Center at UC San Diego Health.
In animal models, tumor-penetrating therapy allows chemotherapy drugs to be delivered deeper inside tumor tissue, increasing effectiveness
Every 12 minutes, someone in the United States dies of pancreatic cancer, which is often diagnosed late, spreads rapidly and has a five-year survival rate at approximately 10 percent. Treatment may involve radiation, surgery and chemotherapy, though often the cancer becomes resistant to drugs.
Researchers at University of California San Diego School of Medicine and Moores Cancer Center, in collaboration with Sanford-Burnham-Prebys Medical Discovery Institute and Columbia University, demonstrated that a new tumor-penetrating therapy, tested in animal models, may enhance the effects of chemotherapy, reduce metastasis and increase survival.
The study, published online March 9, 2021 in Nature Communications, showed how a tumor-targeting peptide, called iRGD, can sneak inside the armor that the tumor built to protect itself and use the fibrous tissue as a highway to reach deeper inside, destroying the tumor from within.
The pancreas is a large gland located behind the stomach. It makes enzymes that aid digestion and hormones that regulate blood-sugar levels. Pancreatic ductal adenocarcinoma (PDAC) is a subtype of pancreatic cancer that is highly drug-resistant due, in part, by the hard shell-like outer layer surrounding the tumor.
“This type of tumor is made up of a dense fibrous tissue that acts as a barrier to drugs trying to get through. Many drugs can reach the vessels of the tumor, but they are not able to get deep into the tissue, making treatment less effective, and that is one reason why this type of cancer is so challenging to treat,” said Tatiana Hurtado de Mendoza, PhD, first author of the study and assistant project scientist at UC San Diego School of Medicine and Moores Cancer Center.
“Our study found that the tumor-penetrating peptide iRGD is able to use this fibrous network to deliver chemotherapy drugs deep into the tumor and be more effective.”
The research team examined the microenvironment of PDAC tumors in a mouse model. They found that after targeting the tumor blood vessels, iRGD binds to high levels of ?5 integrin, a protein produced by cells known as carcinoma-associated fibroblasts (CAFs) that produce much of the tumor’s protective fibrous cover.
“We were able to closely replicate human disease in our mouse model and found that when iRGD was injected with chemotherapy in mice with high levels of ?5 integrin, there was a significant increase in survival and a reduction in the cancer spreading to other organs in the body compared to chemotherapy alone. This could be a powerful treatment strategy to target aggressive pancreatic cancer,” said Andrew Lowy, MD, co-corresponding author of the study, professor of surgery at UC San Diego School of Medicine and chief of the Division of Surgical Oncology at Moores Cancer Center at UC San Diego Health.
“What is also exciting about this finding is the iRGD therapy did not produce any additional side effects. This is critically important when considering treatments for patients.”
The researchers said next steps include a national human clinical trial. They estimate the trial could begin in one year.
“The knowledge gained from our study has the potential to be directly applied to patient care. We also believe that the levels of ?5 integrin within a pancreatic cancer could tell us which patients would benefit the most from iRGD-combination therapy,” said Lowy.
Original Article: Therapy Sneaks into Hard Layer of Pancreatic Cancer Tumor and Destroys it From Within
More from: University of California San Diego School of Medicine | University of California San Diego | Sanford Burnham Prebys Medical Discovery Institute | Columbia University
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Pancreatic cancer
- With prayers and smiles, comedian Tracy Morgan visits cancer patients at Staten Island University Hospital
The entertainer spent time visiting with those of all ages in the medical facility's new Florina Cancer Center.
- Local business owner battling cancer takes part in fundraising walk
In the midst of his own battle against pancreatic cancer, local business owner Kevin Riley traveled to Boston on Saturday where he and thousands of others walked three ...
- Study highlights differences in pancreatic cancer cells based on location
A new study has found that pancreatic cancer cells are different based on their location in the pancreas, providing new information about tumors that could lead to better targeted treatments.
- Pancreatic Cancer: Successful Trial Against Pancreatic Cancer with Defence Therapeutics' ARM-002 Anti-Cancer Vaccine
The vaccine was shown to be therapeutically effective against pre-established pancreatic cancer especially when combined with the anti-PD-1 immune-checkpoint inhibitor. In the context of an in vivo ...
- PanCAN Purplestride United Celebrities, Survivors, Caregivers and Supporters Nationwide at The Ultimate Walk to End Pancreatic Cancer
Lisa Niemi Swayze, Eric Idle, Miss America Madison Marsh, Family of the late Jerry Springer, Team “Trek”, Little House on [...] READ MORE ...
Go deeper with Google Headlines on:
Pancreatic cancer
[google_news title=”” keyword=”pancreatic cancer” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Tumor-penetrating therapy
- Feed has no items.
Go deeper with Google Headlines on:
Tumor-penetrating therapy
[google_news title=”” keyword=”tumor-penetrating therapy” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
[embedyt] https://www.youtube.com/embed?listType=playlist&list=PL0UjJ07OSXC83oV409r1yRju8-ihA1InJ&layout=gallery[/embedyt]